...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Everolimus for Primary Intestinal Lymphangiectasia With Protein-Losing Enteropathy
【24h】

Everolimus for Primary Intestinal Lymphangiectasia With Protein-Losing Enteropathy

机译:依维莫司治疗原发性肠道淋巴管扩张症并伴蛋白丢失性肠病

获取原文
获取原文并翻译 | 示例
           

摘要

Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics. In this article, we describe a 12-year-old boy with PIL that led to protein-losing enteropathy characterized by diarrhea, hypoalbuminemia associated with edema (serum albumin level: 1.0 g/dL), and hypogammaglobulinemia (serum IgG level: 144 mg/dL). Severe hypoalbuminemia, electrolyte abnormalities, and tetany persisted despite a low-fat diet and propranolol. Everolimus (1.6 mg/m(2)/day) was added to his treatment as an antiangiogenic agent. With everolimus treatment, the patient's diarrhea resolved and replacement therapy for hypoproteinemia was less frequent. Hematologic and scintigraphy findings also improved (serum albumin level: 2.5 g/dL). There were no adverse reactions during the 12-month follow-up. To the best of our knowledge, this is the first report of everolimus use in a patient with PIL.
机译:原发性肠淋巴管扩张症(PIL),也称为Waldmann病,是一种由于肠淋巴管形态异常而引起的渗出性肠病。在本文中,我们描述了一个12岁的PIL男孩,该男孩导致蛋白质丢失性肠病,其特征为腹泻,伴有水肿的低白蛋白血症(血清白蛋白水平:1.0 g / dL)和低血球蛋白(血清IgG水平:144 mg) / dL)。尽管低脂饮食和心得安仍严重存在严重的低白蛋白血症,电解质异常和破伤风。依维莫司(1.6 mg / m(2)/天)被添加为抗血管生成剂。依维莫司治疗后,腹泻得到缓解,低蛋白血症的替代治疗频率降低。血液学和闪烁显像检查结果也有所改善(血清白蛋白水平:2.5 g / dL)。在12个月的随访期间没有不良反应。据我们所知,这是PIL患者使用依维莫司的首例报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号